Product image of Icatibant supplied by GNH India

Icatibant

Active Ingredient:
Icatibant
Origin:
EU

Icatibant

Icatibant, the active ingredient in the product Icatibant, is a bradykinin B2 receptor antagonist presented as a 30 mg (0.3 mL) subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH India supplies Icatibant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled product handling and regulatory compliance. The company provides robust cold‑chain logistics and comprehensive documentation to meet global market requirements.

Manufacturer / TM Owner

Mylan S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

  • Hereditary angioedema (HAE) acute attacks: Provides rapid relief of swelling episodes in adult patients.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor. By binding to this receptor it blocks the actions of bradykinin, preventing the vasodilation and increased vascular permeability that lead to the swelling characteristic of hereditary angioedema attacks.

Side Effects

Common side effects are generally mild and related to the injection site or transient systemic reactions.

Common Side Effects

  • Injection site pain: discomfort at the site of administration.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: mild edema around the injection.
  • Nausea: occasional feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical care.
  • Severe angioedema: unexpected swelling beyond intended effect.
  • Hypotension: notable drop in blood pressure.
  • Urticaria: hives or widespread skin rash.
  • Severe injection‑site reaction: necrosis or infection.
  • Infection: localized or systemic infection at the injection site.

Precautions & Warnings

Precautions should be observed to minimize risk and ensure safe use.

  • Pregnancy: safety not established; use only if benefit outweighs potential risk.
  • Breastfeeding: unknown safety; consider caution.
  • Renal impairment: monitor as drug clearance may be reduced.
  • Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; monitor for angioedema.
  • Known hypersensitivity: avoid use in patients with documented allergy to icatibant or its excipients.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medications that affect bradykinin pathways or fluid balance.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effect may raise angioedema risk.
  • Angiotensin receptor blockers (ARBs): similar potential to increase bradykinin‑mediated reactions.
  • Other bradykinin B2 antagonists: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely)

  • Diuretics: may alter fluid balance and blood pressure.
  • Corticosteroids: could mask signs of infection.
  • Antihistamines: may modify response to allergic symptoms.

Frequently Asked Questions

Icatibant is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult patients. It rapidly reduces the swelling associated with HAE episodes by blocking the effects of bradykinin.

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dose of icatibant is set by the prescribing healthcare professional. Typically, a single 30 mg subcutaneous injection is given for an acute HAE attack, with additional doses administered only under medical supervision if required.

Safety data for icatibant during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative for acute HAE attacks is C1‑esterase inhibitor replacement therapy. Icatibant directly blocks bradykinin receptors, offering a rapid subcutaneous option, whereas C1‑esterase inhibitors replace the deficient protein and are administered intravenously or subcutaneously.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light. It must not be frozen or shaken. Keep the product in its original packaging until use and discard after the expiration date.

Icatibant is administered as a subcutaneous injection into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient using the prefilled syringe provided with the product, following aseptic technique.

Serious or rare adverse reactions may include anaphylaxis, severe angioedema, hypotension, urticaria, and severe injection‑site reactions. Patients should be monitored for signs of allergic response and seek immediate medical attention if any of these occur.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe renal impairment, pregnant or breastfeeding women, and those taking ACE inhibitors or ARBs due to potential additive bradykinin effects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT